SEC Form 4 · accession 0001209191-18-058716
ALBIREO PHARMA, INC. · ALBO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ronald Harold Wilfred Cooper
Officer — President and CEO · Director
Period of report
Nov 13, 2018
Accepted (ET)
Nov 15, 2018 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001322505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Nov 13, 2018 | P | 1,026 | $25.0177 | A | 7,760 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2018.
- F2This transaction was executed in multiple trades at prices ranging from $24.85 to $25.14. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.